In Week of Mar 28, 2026, Rubicon Research Ltd (Pharma - Formulators) is outperforming Nifty 500 with +24.2% relative strength. Fundamentals: Average. On a 10-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: New manufacturing facility coming online to relieve capacity constraints
Impact: +₹225 Cr revenue
“Pithampur facility expected to be operational by mid-2026, with commercialization in Q1 CY27”
What: Higher-margin specialty products now 31-32% of gross profit vs 26.9% in FY25
Impact: +₹60 Cr revenue
“Specialty share of gross profit at 31-32% vs 26.9% in FY25 full year”
What: R&D investment returns increased from 3.3x to 5.7x over rolling periods
Impact: +₹40 Cr revenue
“R&D productivity improving with investment returns increasing from 3.3x to 5.7x”
Earnings deceleration risks from management commentary
Trigger: Continued near-100% capacity utilization
Impact: -150 bps margin impact
Management view: Operating margins remain resilient in 22-23% range despite gross margin pressure
Monitor: Capacity utilization %
Trigger: Slow conversion of inventory to sales
Impact: -50 bps margin impact
Management view: Inventory viewed as fuel for growth and covering upcoming launches
Monitor: Inventory turnover days
Key quotes from recent conference calls
“The Pithampur manufacturing facility is on track for operationalization by mid-2026, with commercialization expected in Q1 CY27 — Management”
“We stand by that the operating EBITDA margin would remain stable and we stand by that the revenue ramp up is obviously stronger than what we have in discussed — CFO Nitin Jajodia”
“USD revenue of $53 million, up 46% year-on-year, with approximately 98% of revenue denominated in U.S. dollars — Management”
“The company reiterated its guidance for operating EBITDA margins to remain stable between 22% to 23% and R&D expenses to be around 10% to 11% of revenue for the next several years — Management”
Forward-looking targets from management for next 2-4 quarters
OPM Guidance
22.5%
Key Milestones
• Pithampur facility operational by mid-2026
• Commercialization in Q1 CY27
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +52% | +60% | Insufficient Data |
| PAT (Net Profit) | +92% | +61% | Insufficient Data |
| OPM | 23.0% | +100 bps | Expanding |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Rubicon Research Ltd's latest quarterly results (Dec 2025) show
Rubicon Research Ltd's profit is growing with an insufficient_data trend.
Rubicon Research Ltd's revenue growth trend is insufficient_data.
Rubicon Research Ltd's operating margin is expanding.
Rubicon Research Ltd's long-term compounding rates
Rubicon Research Ltd's earnings growth is insufficient_data with strong momentum on a sequential basis.
Rubicon Research Ltd appears overvalued based on our fair value analysis.
Rubicon Research Ltd's current PE ratio is 75.1x.
Rubicon Research Ltd's current PE is 75.1x.
Rubicon Research Ltd's price-to-book ratio is 19.5x.
Rubicon Research Ltd is rated Average with a fundamental score of 48/100. This score is calculated from objective financial metrics
Rubicon Research Ltd has a debt-to-equity ratio of N/A.
Rubicon Research Ltd's return ratios over recent years
Rubicon Research Ltd's operating cash flow is positive (FY2025).
Rubicon Research Ltd currently does not pay a significant dividend (yield 0.00%).
Rubicon Research Ltd's shareholding pattern (Dec 2025)
Rubicon Research Ltd has been outperforming Nifty 500 for 10 consecutive weeks, indicating consistent outperformance.
Rubicon Research Ltd is an established outperformer with 10 weeks of consecutive Nifty 500 outperformance.
Rubicon Research Ltd has 3 key growth catalysts identified from recent earnings analysis
Rubicon Research Ltd has 2 key risks worth monitoring
In Q3 FY26, Rubicon Research Ltd's management highlighted
Rubicon Research Ltd's management has provided the following forward guidance for next 2-4 quarters
Based on quantitative research signals, here is why Rubicon Research Ltd may be worth studying
Rubicon Research Ltd investment thesis summary:
Rubicon Research Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
